---
layout: default
title: Caffeine
parent: 僅模型預測 (L5)
nav_order: 130
evidence_level: L5
indication_count: 10
---

# Caffeine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Caffeine: From Apnea of Prematurity to Nasal Cavity Disease

## One-Sentence Summary

Caffeine is a methylxanthine compound and non-selective adenosine receptor antagonist, pharmaceutically established for neonatal apnea of prematurity and widely used as an analgesic adjuvant; it holds no registered indication in India.
The TxGNN model predicts it may be effective for **Nasal Cavity Disease**, with **0 clinical trials** and **3 publications** currently supporting this direction.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No registered indication in India (global pharmaceutical uses include apnea of prematurity and analgesic adjuvant) |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacology, caffeine is a methylxanthine that functions as a non-selective competitive antagonist at adenosine A1 and A2A receptors, and at higher concentrations also inhibits phosphodiesterase (PDE), elevating intracellular cAMP. Its efficacy in neonatal apnea of prematurity (via respiratory center stimulation) and as an analgesic adjuvant has been well established clinically. Mechanistically, these same pathways may be relevant to nasal cavity disease.

Adenosine receptors (A1/A2A) are distributed throughout nasal mucosal tissues, where they participate in vascular tone regulation, mucus secretion, and local inflammatory signalling. Caffeine's antagonism of these receptors could theoretically modulate mucosal oedema or inflammatory mediator release relevant to nasal pathology. Separately, bitter taste receptors (TAS2R), which caffeine may activate given its bitter profile, have been described in nasal cavity epithelium and are thought to influence mucosal immune defence and ciliary function.

However, the mechanistic link remains highly indirect. Available literature primarily examines caffeine as a payload in nasal drug delivery systems (e.g., intranasal thermo-sensitive gels for CNS effects), not as an active therapeutic agent targeting nasal cavity pathology. No controlled clinical research in this indication exists, and the prediction must be interpreted as hypothesis-generating only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for caffeine in nasal cavity disease.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|-------------|
| [35579146](https://pubmed.ncbi.nlm.nih.gov/35579146/) | 2022 | Formulation / Preclinical | Current Drug Delivery | Developed an intranasal caffeine thermo-sensitive in situ gel to enhance cognition after sleep deprivation; confirms nasal mucosal permeability to caffeine but addresses drug delivery rather than treatment of nasal cavity disease itself |
| [26272040](https://pubmed.ncbi.nlm.nih.gov/26272040/) | 2015 | Review | Pharmacology & Therapeutics | Reviews the pharmacology of bitter taste receptors (T2Rs); describes T2R expression in nasal cavity, lung, and other extra-oral tissues — provides theoretical receptor-level rationale for caffeine activity at nasal epithelium |
| [9751618](https://pubmed.ncbi.nlm.nih.gov/9751618/) | 1998 | Animal Study | Cancer Research | 2-year rat bioassay showing caffeine attenuates NNK-induced lung tumorigenesis; demonstrates caffeine biological activity in respiratory tissue at the preclinical level, though the disease model (lung carcinogenesis) differs considerably from nasal cavity disease |

---

## India Market Information

Caffeine (DrugBank ID: DB00201) currently holds **no registered product licences** in India and is classified as **not marketed**. There are no approved branded formulations or regulatory submissions on record for this jurisdiction.

---

## Safety Considerations

**Drug Interactions** (75 total interactions identified in DDInter database; key interactions listed below):

| Interacting Drug | Severity | Clinical Significance |
|----------------|---------|----------------------|
| Cocaine (nasal) | **Major** | Additive sympathomimetic stimulation; significant cardiovascular risk |
| Cocaine (topical) | **Major** | Additive sympathomimetic stimulation; significant cardiovascular risk |
| Adenosine | Moderate | Caffeine competitively antagonises adenosine's vasodilatory effect — avoid caffeine before adenosine cardiac stress testing |
| Dipyridamole | Moderate | Caffeine blocks dipyridamole-induced coronary vasodilation, invalidating pharmacological stress tests; caffeine must be withheld prior to dipyridamole imaging |
| Ciprofloxacin | Moderate | CYP1A2 inhibition by ciprofloxacin significantly raises caffeine plasma levels; monitor for caffeine toxicity (tachycardia, insomnia, anxiety) |
| Abametapir (topical) | Moderate | CYP1A2 inhibition may substantially increase systemic caffeine concentrations |
| Capmatinib | Moderate | MATE1/2-K transporter interaction may alter caffeine pharmacokinetics |
| Anagrelide | Moderate | Additive PDE inhibition may exacerbate cardiovascular effects |
| Bendamustine | Moderate | Potential for altered hepatic CYP1A2-mediated metabolism |
| Cycloserine | Moderate | Enhanced CNS stimulation; risk of seizure threshold lowering |
| Duloxetine | Moderate | CYP1A2 substrate competition; monitor caffeine plasma levels |
| Alosetron | Moderate | CYP1A2 inhibition by alosetron may elevate caffeine exposure |
| Obeticholic acid | Moderate | Pharmacokinetic interaction via hepatic transporter pathways |
| Acetylsalicylic acid | Minor | Well-characterised synergistic analgesic combination; generally favourable |
| Cimetidine | Minor | Mild CYP1A2 inhibition; minor increase in caffeine half-life |
| Atazanavir | Minor | Modest CYP interaction; routine monitoring sufficient |
| Disulfiram | Minor | Reduced caffeine clearance; caffeine levels may rise modestly |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN prediction score of 99.91%, the evidence base for caffeine in nasal cavity disease is limited to L4 — comprising a drug delivery formulation study, a receptor biology review, and a respiratory tissue animal model. The mechanistic connection is speculative and indirect, and no clinical trial data exists to support this indication. Proceeding to the next evaluation stage is not warranted without further mechanistic and preclinical evidence.

**To proceed, the following is needed:**
- Retrieve detailed pharmacological MOA data from DrugBank API (flagged as Data Gap DG002)
- Retrieve CDSCO/TFDA package insert warnings and contraindications (flagged as Blocking Data Gap DG001)
- Define the specific subtype of nasal cavity disease being targeted (e.g., chronic rhinitis, allergic rhinitis, sinonasal neoplasm, nasal polyps) — each carries a distinct mechanistic rationale
- Commission or identify preclinical proof-of-concept studies demonstrating caffeine's direct therapeutic activity in nasal mucosal or sinonasal cell models
- Evaluate the optimal route of administration (intranasal vs. systemic oral) and whether existing nasal delivery formulations provide therapeutic vs. pharmacokinetic benefits
- Assess India regulatory pathway and requirements for a drug with zero existing domestic registrations before any further development investment

> ⚠️ **Disclaimer:** This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

